GEN Exclusives

More »

GEN News Highlights

More »
Sep 24, 2008

Teva and Kowa to Set Up Generic Firm in Japan

  • Teva Pharmaceutical and Kowa signed a definitive agreement to establish a generic pharmaceutical company in Japan. Sales from the new entity, Teva-Kowa Pharma, are expected to reach $1 billion in 2015.

    Teva and Kowa will each have a 50% stake in the new firm, which will become operational in 2009. Teva-Kowa Pharma will leverage the marketing, R&D, manufacturing, and distribution capabilities of each company.

    “Combining Kowa's knowledge of and established reputation within the Japanese market with Teva's global leadership and expertise in generics should enable us to maximize the opportunity available in this important growth market,” says Shlomo Yanai, Teva's president and CEO. “Our objective is to provide the Japanese generic market, which is expected to double in volume in the next five years, with high-quality and affordable pharmaceuticals, supporting the government's stated objective of increasing generic penetration.”

    Japan is the second largest pharmaceutical market in the world, valued at approximately $80 billion, according to the companies. In 2006, generics represented 5.7% in value of this market, or approximately $4.6 billion, and 16.9% in volume as per IMS and data from the Japanese Generics Manufacturing Association. In 2007, the Ministry of Finance reported a plan to double generic utilization to 30% by 2012


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »